ThirdAge Services LLC

What a payday for unscrupulous entrepreneurs!

Study shows half of middle-aged Americans fear they’ll get dementia, use unproven supplements Authors warn that overestimating one’s own risk, combined with an embrace of ineffective preventive measures, could lead to a lot of wasted spending.

Is this a surprise? not to me!

CMS Prefers Saving Money to Saving Lives Kevin Campbell says agency bases decisions on obsolete data

Oh so very true. Which is why I've counseled my clients to NEVER! EVER! EVER! sign up for one.

Medicare Advantage Enrollees Discover Dirty Little Secret Getting out is a lot harder than getting in

Very interesting research! When you think about it, it makes sense too. Maybe it will lead somewhere.

Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep During non–rapid eye movement sleep, low-frequency oscillations in neural activity support memory consolidation and neuronal computation. Sleep is also associated with increased interstitial fluid volume and clearance of metabolic waste products. It is unknown why these processes co-occur and how ...

Again folks with dementia are fleeced as well...

Allergan shelling out $750M to settle lawsuit over its Namenda 'hard switch' campaign At the price of a $750 million, Allergan has avoided a trial over its effort to force patients onto a newer version of Namenda as the original neared the patent cliff. The drugmaker will pony up to settle allegations that it delayed cheap Namenda generics with its 'hard switch' plan, costing purchas...

I wonder how much they made before agreeing to this settlement?

Avanir Pharmaceuticals agreed to pay more than $95 million to resolve kickback allegations and charges of "false and misleading marketing" of dextromethorphan-quinidine (Nuedexta) to manage dementia behavior, an unapproved indication, the Justice Department announced.
Just one day later, Avanir reported its phase III trial of deudextromethorphan hydrobromide-quinidine sulfate -- a version of Nuedexta -- failed at treating agitation in Alzheimer's patients.

Bravo! Love it!

At Amazon's PillPack pharmacy, new hires do 'empathy training' by sorting pills while wearing bulky gloves and glasses CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.

When you read the whole article the headline becomes "less true and less meaningful" in day to day detection or screening for Alzheimer's. This is another example of headline Truthiness rather then the whole truth.

Alzheimer's Blood Test Shows 94% Accuracy Mass spectrometry assay and genetic screen predict brain amyloidosis

Hmmm. Still chasing the less hospitalization thing for cost cutting, instead of paying primary care Doctors who take Medicare enough to keep their practices open

Medicare's 'Primary Care First' Program Has Its Skeptics Too much focus on cutting hospitalizations, not enough $$ for docs, critics say

Here’s a really, really excellent article on research on how to create empathy for older adults with disabilities. Everyone will probably love reading it except P.K. Beeville and the folks at the Virtual Dementia Tour. They’ll probably sue the hell out of this research department.

Can We Live Longer but Stay Younger? With greater longevity, the quest to avoid the infirmities of aging is more urgent than ever.

Want to know how many years you'll live from right now? How many of those years you'll be disabled and need care? Here's an interactive calculator from the University of Connecticut Actuarial Research department. Try it! I have 24 year from now and 8 years of disability. What about you? https://lnkd.in/efQNGgU #

HLE Calculator

This could be a whole new ball game in research on Alzheimers. Researchers found differences in how genes worked in Myelination (the fatty coating on parts of brain cells) . Myelination is also screwed up in MS (multiple sclerosis) in a few research subjects at MIT. Here's a quote from the leader of the study.

" The team also compared differences in gene expression between early-stage and late-stage Alzheimer’s disease. They identified distinct changes in all the major cell types early in the disease process. Genetic signatures related to myelination were affected in most cell types, suggesting a key role in the disease.

“This study provides, in my view, the very first map for going after all of the molecular processes that are altered in Alzheimer’s disease in every single cell type that we can now reliably characterize,” Kellis says. “It opens up a completely new era for understanding Alzheimer’s.”

—by Geri Piazza